Brain-Targeted Codelivery of Bcl-2/Bcl-xl and Mcl-1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy
- 30 March 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 16 (4) , 6293-6308
Abstract
Glioblastoma (GBM) is among the most treatment-resistant solid tumors and often recurrs after resection. One of the mechanisms through which GBM escapes various treatment modalities is the overexpression of anti-apoptotic Bcl-2 family proteins (e.g., Bcl-2, Bcl-xl, and Mcl-1) in tumor cells. Small-molecule inhibitors such as ABT-263 (ABT), which can promote mitochondrial-mediated cell apoptosis by selectively inhibiting the function of Bcl-2 and Bcl-xl, have been proven to be promising anticancer agents in clinical trials. However, the therapeutic prospects of ABT for GBM treatment are hampered by its limited blood–brain barrier (BBB) penetration, dose-dependent thrombocytopenia, and the drug resistance driven by Mcl-1, which is overexpressed in GBM cells and further upregulated upon treatment with ABT. Herein, we reported that the Mcl-1-specific inhibitor A-1210477 (A12) can act synergistically with ABT to induce potent cell apoptosis in U87 MG cells, drug-resistant U251 cells, and patient-derived GBM cancer stem cells. We further designed a biomimetic nanomedicine, based on the apolipoprotein E (ApoE) peptide-decorated red blood cell membrane and pH-sensitive dextran nanoparticles, for the brain-targeted delivery of ABT and A12. The synergistic anti-GBM effect was retained after encapsulation in the nanomedicine. Additionally, the obtained nanomedicine possessed good biocompatibility, exhibited efficient BBB penetration, and could effectively suppress tumor growth and prolong the survival time of mice bearing orthotopic GBM xenografts without inducing detectable adverse effects.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2018YFA0209800)
- China Postdoctoral Science Foundation (2019M662483)
- National Natural Science Foundation of China (31800841, 32071388, 32101152, 51803049, U2004171)
- Program for Science & Technology Innovation Talents in Universities of Henan Province (21HASTIT033)
This publication has 67 references indexed in Scilit:
- Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticlesNanoscale, 2013
- Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platformProceedings of the National Academy of Sciences, 2011
- Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidizationProceedings of the National Academy of Sciences, 2010
- Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer TherapyClinical Cancer Research, 2009
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family InhibitorCancer Research, 2008
- Anti-Apoptosis Mechanisms in Malignant GliomasJournal of Clinical Oncology, 2008
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemiaCancer Cell, 2006
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- Two Apolipoprotein E Mimetic Peptides, ApoE(130−149) and ApoE(141−155)2, Bind to LRP1Biochemistry, 2004